NDRAU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NDRAU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ENDRA Life Sciences has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate ENDRA Life Sciences's interest coverage with the available data. As of today, ENDRA Life Sciences's Altman Z-Score is 0.00.
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
ENDRA Life Sciences's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-2.78 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.15 Mil.
ENDRA Life Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is
GuruFocus does not calculate ENDRA Life Sciences's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. ENDRA Life Sciences Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
ENDRA Life Sciences's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.178 | + | 0.146) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
ENDRA Life Sciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NAS:NDRAU) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
ENDRA Life Sciences has the Financial Strength Rank of 0.
Thank you for viewing the detailed overview of ENDRA Life Sciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Renaud Bertrand Maloberti | officer: Chief Commercial Officer | 10 ACORN WAY, GEORGETOWN MA 01833 |
Anthony Digiandomenico | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Michael Milos Thornton | officer: Chief Technology Officer | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
David R. Wells | officer: Chief Financial Officer | 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
Francois Roger Michelon | director, officer: Chief Executive Officer | 430 N. JUNO LANE, JUNO BEACH FL 33406 |
Michael Harsh | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Lou Basenese | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Alexander Y Tokman | director | C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
Sanjiv Sam Gambhir | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Longboard Capital Advisors, Llc | 10 percent owner | 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
Brett Conrad | 10 percent owner | 1312 CEDAR ST., SANTA MONICA CA 90405 |
From GuruFocus
By Business Wire • 11-29-2023
By Business Wire Business Wire • 06-08-2022
By Business Wire • 08-23-2023
By Business Wire Business Wire • 05-10-2022
By Business Wire • 11-06-2023
By Business Wire Business Wire • 08-02-2022
By Business Wire Business Wire • 05-02-2023
By Business Wire Business Wire • 06-07-2023
By Business Wire • 08-30-2023
By Business Wire • 11-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.